ESC Premium Access

Sex-specific analysis on efficacy and safety of statins: a systematic review and quantitative meta-analysis

Congress Presentation

About the speaker

Miss Michelle Schreuder

Erasmus University Medical Centre, Rotterdam (Netherlands (The))
0 follower

5 more presentations in this session

Changes in plasma lipid species following pravastatin treatment predict cardiovascular outcomes and represent a measure of the relative risk reduction in secondary prevention

Speaker: Professor P. Meikle (Melbourne, AU)


Empagliflozin reduces mortality in patients with type 2 diabetes and a history of left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial

Speaker: Professor S. Verma (Toronto, CA)


LDL-C treatment patterns and associated outcomes in patients with type 2 diabetes and CVD: insights from TECOS

Speaker: Professor G. De Ferrari (Turin, IT)


Reduction in systolic blood pressure with semaglutide treatment is not due to weight loss alone: data from SUSTAIN 1-5

Speaker: Professor S. Bain (Swansea, GB)


Empagliflozin reduces mortality and hospitalisation for heart failure irrespective of cardiovascular risk score at baseline

Speaker: Doctor D. Fitchett (Toronto, CA)


Access the full session

Poster Session 2 - Cardiovascular risk and its modification

Speakers: Miss M. Schreuder, Professor P. Meikle, Professor S. Verma, Professor G. De Ferrari, Professor S. Bain...

About the event


ESC Congress 2018

7 November - 29 August 2018

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb